Searchable abstracts of presentations at key conferences in endocrinology

ea0032p869 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

The effect of the ANKK1/DRD2 Taq1A polymorphism on metabolic side effects of dopaminergic treatment in PRL adenomas

Athanasoulia Anastasia P , Sievers Caroline , Uhr Manfred , Stalla Gunter , Schneider Harald

Introduction: Treatment with dopamine agonists in patients with PRL adenomas has been associated with weight loss in short-term studies. However, long-term studies on weight changes are lacking. Taq1A is a restriction fragment length polymorphism considered as a gene marker for the D2DR gene. The presence of at least one A1 allele is linked to reduced brain dopaminergic activity due to reduced receptor binding and lower density of the dopamine two receptor.<p clas...